Reviva Pharmaceuticals (NASDAQ:RVPH) Announces Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Reviva Pharmaceuticals (NASDAQ:RVPH) posted its earnings results on Saturday. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.37, FiscalAI reports.

Reviva Pharmaceuticals Stock Performance

NASDAQ RVPH opened at $0.74 on Monday. Reviva Pharmaceuticals has a 52-week low of $0.67 and a 52-week high of $23.20. The company has a market capitalization of $4.78 million, a P/E ratio of -0.08 and a beta of 0.10. The company has a fifty day moving average of $4.27 and a 200-day moving average of $7.91.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on RVPH. D. Boral Capital lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Wall Street Zen upgraded Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, March 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Chardan Capital restated a “buy” rating and issued a $40.00 target price on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $66.67.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC bought a new stake in Reviva Pharmaceuticals during the first quarter worth about $58,000. XTX Topco Ltd purchased a new position in shares of Reviva Pharmaceuticals during the 2nd quarter valued at about $31,000. Lido Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals during the 3rd quarter valued at about $37,000. State Street Corp lifted its position in Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after buying an additional 256,500 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares in the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.